Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22150105 | 1.00 | PRCP (0.37) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL16342611 | 1.00 | PRCP (0.37) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL17825459 | 1.00 | PRCP (0.37) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL16295882 | 0.94 | PYGL (0.38) | PRCPFPR2ITGB3ITGA2BACE2 | |
| SCHEMBL16343488 | 0.94 | PYGL (0.38) | PRCPFPR2ITGB3ITGA2BACE2 | |
| SCHEMBL16306082 | 0.93 | PRCP (0.42) | PRCPFPR2KMT2AACKR3F10 | |
| SCHEMBL16306070 | 0.92 | F10 (0.39) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL28532158 | 0.92 | F10 (0.39) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL28532160 | 0.92 | F10 (0.39) | PRCPFPR2ITGB3ITGA2BKMT2A | |
| SCHEMBL17945643 | 0.92 | F10 (0.39) | PRCPFPR2ITGB3ITGA2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074820-B | GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112457301-A | Novel GLP-1 receptor modulators | 赛尔基因第二国际有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3008056-B1 | NOVEL GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-12-09 | — | — | EP | disclosed |
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-10259823-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-04-16 | — | — | US | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-9260427-B2 | GLP-1 receptor modulators | RECEPTOS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 600/4885FPR2 492/4885ITGB3 4025/4885 |
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 600/4885FPR2 492/4885ITGB3 4025/4885 |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 926/4885FPR2 740/4885ITGB3 3314/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 600/4885FPR2 492/4885ITGB3 4025/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 600/4885FPR2 492/4885ITGB3 4025/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PRCP 775/4885FPR2 499/4885ITGB3 3678/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 926/4885FPR2 740/4885ITGB3 3314/4885 |
| US-10259823-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | PRCP 775/4885FPR2 499/4885ITGB3 3678/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | PRCP 600/4885FPR2 492/4885ITGB3 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.